Neurocrine stockholders elect directors, approve say-on-pay, amended equity plan, ratify EY

NEUROCRINE BIOSCIENCES INC

All four Class I directors elected: Rastetter, Morrow, Norwalk, Poon; each received >72M votes.
Advisory say-on-pay passed with ~80.3M for vs 4.3M against.
Amended 2020 Equity Incentive Plan approved (76.1M for, 9.5M against).
Ernst & Young ratified as auditor for FY2024 with 84.6M for, 5.5M against.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.